Ulcerative Colitis news | Breaking ulcerative colitis news

ViroPharma Shares 'Absolute Floor' Seen At $9 to $10

..."We believe that the generic risk to Vancocin will continue to remain an overhang on the stock until there is further clarity on the company's petition and/or pipeline opportunities to offset the loss in revenues from generic Vancocin," said Wei.

"We remain encouraged that maribavir and/or the company's stellar business development track record will be successful long term, and progress with either effort could sway our investment thesis, given what we see as a $9 to $10 absolute floor on the valuation from Vancocin and current cash alone."Maribavir is an experimental antiviral drug acquired from GlaxoSmithKline (nyse: GSK - news - people ) in 2003.

ViroPharma previously said it expects to release preliminary results of a Phase II study before the end of the month.ViroPharma acquired the U.S.

rights to Vancocin from Eli Lilly (nyse: LLY - news - people ) in December 2004.

Earlier this month, AstraZeneca (nyse: AZN - news - people ) said it acquired the rights to Vancocin for the India and Nepal markets for an undisclosed sum.

More On This Topic Companies: VPHM AZN -% String xsl=(String) application.getAttribute(com.forbes.cms.Constants.XSL_REP_KEY)+"/story_body_html_trans.xsl"; final TransformerFactory tFactory = TransformerFactory.newInstance(); final Transformer transform...

Ulcerative Colitis

News

Advertisers:

ViroPharma Shares 'Absolute Floor' Seen At $9 to $10